Skip to main content

Gilead Sciences, Inc. (GILD) Stock Analysis

Temp Headwind edge

HoldModerate Confidence

Healthcare · Drug Manufacturers - General

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Hold if already holding. Not a fresh buy at $131.33, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV.

Gilead Sciences is a biopharmaceutical company with 25+ commercial products across HIV (Biktarvy, Descovy), viral hepatitis (Epclusa, Vemlidy), and oncology (Yescarta, Trodelvy), operating in 35+ countries. HIV products generate a substantial portion of revenue, distributed... Read more

$131.33+8.6% A.UpsideScore 6.2/10#2 of 16 Drug Manufacturers - General
Stop $125.31Target $142.52(analyst − 10%)A.R:R 1.7:1
Analyst target$158.36+20.6%28 analysts
$142.52our TP
$131.33price
$158.36mean
$123
$180

Hold if already holding. Not a fresh buy at $131.33, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.

Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: conservative.

Val7.3Qual8.0Grw5.2Mom2.7Sent7.2Ins5.0Peer5.3Tech7.3Risk6.86.2OVERALL

Thesis

Rewards
Strong earnings beat streak (4/4)
High-quality business
Attractive valuation
Risks
Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%)
Concentration risk — Product: HIV
Thin upside margin: 8.6%

Key Metrics

P/E (TTM)19.0
P/E (Fwd)13.4
Mkt Cap$159.9B
EV/EBITDA12.1
Profit Mgn28.9%
ROE40.7%
Rev Growth4.7%
Beta0.40
Dividend2.55%
Rating analysts39

Quality Signals

Piotroski F8/9

Options Flow

P/C1.16bearish
IV46%normal
Max Pain$160+21.8% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHCustomerCardinal Health, Cencora, McKesson90%
    10-K Item 1A: 'approximately 90% of our gross product sales in the U.S. have been to three wholesalers—Cardinal Health, Inc., Cencora, Inc. and McKesson Corporation'
  • HIGHProductHIV
    10-K Item 1A: 'We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
4.0
Rsi
8.4
Uptrend pullback (RSI 31) - buy opportunityVolume distribution (falling OBV)Above 200-day MA
GatesMomentum 2.7<4.5EARNINGS PROXIMITY 7d<=7dA.R:R 1.7 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARSuitability: Conservative
RSI
31 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $127.64Resistance $142.97

Price Targets

$125
$143
A.Upside+8.5%
A.R:R1.7:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Momentum score 2.7/10 — below 4.5 minimum
! EARNINGS_PROXIMITY:7d<=7d

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is GILD stock a buy right now?

Hold if already holding. Not a fresh buy at $131.33, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $142.52 (+8.5%), stop $125.31 (−4.8%), A.R:R 1.7:1. Score 6.2/10, moderate confidence.

What is the GILD stock price target?

Take-profit target: $142.52 (+8.6% upside). Target $142.52 (+8.5%), stop $125.31 (−4.8%), A.R:R 1.7:1. Stop-loss: $125.31.

What are the risks of investing in GILD?

Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV; Thin upside margin: 8.6%.

Is GILD overvalued or undervalued?

Gilead Sciences, Inc. trades at a P/E of 19.0 (forward 13.4). TrendMatrix value score: 7.3/10. Verdict: Hold.

What do analysts say about GILD?

39 analysts cover GILD with a consensus score of 4.1/5. Average price target: $158.

What does Gilead Sciences, Inc. do?Gilead Sciences is a biopharmaceutical company with 25+ commercial products across HIV (Biktarvy, Descovy), viral...

Gilead Sciences is a biopharmaceutical company with 25+ commercial products across HIV (Biktarvy, Descovy), viral hepatitis (Epclusa, Vemlidy), and oncology (Yescarta, Trodelvy), operating in 35+ countries. HIV products generate a substantial portion of revenue, distributed primarily through three U.S. wholesalers (Cardinal Health, Cencora, McKesson).

Related stocks: LLY (Eli Lilly and Company) · GSK (GSK plc) · AMGN (Amgen Inc.) · BIIB (Biogen Inc.) · AZN (AstraZeneca PLC)